UNSPSC 51432200: Antihypertensive hydralazines

Antihypertensive drugs made from a direct-acting vasodilator, pyridazine, phthalazine, and hydrazinophthalazine, hence the name HYDRA-LAZINE, HYDRA-LAZINES, and HYDRALAZINE.

UNSPSC 51432200 Antihypertensive hydralazines is a Class code covering pharmaceutical products used in emergency medical response and state health benefit programs. State and local government procurement under this code focuses on acquiring specific antihypertensive medications for use by fire rescue departments, emergency medical services, and state pharmacy benefit programs. The City of Tampa's April 2026 bid for Advanced Life Support Medications demonstrates the typical scope: emergency responders require multiple cardiac and antihypertensive agents (including labetalol, adenosine, and diltiazem) with firm expiration dates nine months or longer and rapid delivery within ten calendar days. Issuing bodies include municipal purchasing departments acting on behalf of fire rescue operations, state health and human services agencies managing pharmacy benefit programs, and multistate cooperative purchasing consortiums. The City of Tampa and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) represent the mix of municipal and regional cooperative vehicles active in this space.

Recent activity concentrates in Florida and Minnesota, with emerging cross-state coordination through cooperative purchasing. The City of Tampa issued IFB 26P00188 with a response deadline of April 8, 2026 and an estimated contract value of $40,000 for one-year supply agreements with options to renew for two additional one-year periods plus three 30-day extensions; the bid included a 5 percent Small Local Business Enterprise (SLBE) discount not to exceed $10,000. The Minnesota Department of Administration, through MMCAP, issued RFP S1070000015802 with a March 26, 2026 response deadline for multi-state generic pharmaceutical procurement effective July 1, 2026, requiring vendors to maintain relationships with three authorized wholesalers and certify compliance with cGMP and DSCSA standards. The Texas Health and Human Services Commission issued RFI HHS0017013 in March 2026 to explore direct-to-manufacturer prescription contracting models for future state-level pharmacy initiatives, signaling expansion of demand beyond traditional cooperative purchasing channels.